Newsroom
News Releases
Featured Research: 2024 International Congress
September 27, 2024
View previous International Congress news releases
September 2023
Featured abstracts:
- Diabetes treatment shows potential as an adjunct therapy for early Parkinson’s disease
- First Tunisian study examining age of onset for biallelic mutations in Huntington’s disease
- Machine learning algorithm applied in classifying tic from non-tic movements
- Machine learnings has potential to assist with diagnosis in Parkinsonian syndromes
- Novel application of machine learning approaches predicts gait dysfunction in Parkinson’s disease
- Safety and efficacy of gene therapy studied in minipigs with Huntington’s disease
- Three months of probiotic therapy shown to reduce motor and nonmotor Parkinson’s disease symptoms
MDS journal news:
- MDS Task Force on Pediatrics publishes recommendations for transitional care for young people with movement disorders
- New data validates an association between trauma-related disorders and the development of Parkinson’s disease in military veterans
September 15, 2022
- Short-term study of Ecopipam Shows Reduction of Tics in Children with Tourette Syndrome
- Regardless of Type, Exercise Improve Quality of Life and Motor Function in People with Parkinson’s Disease
- Climbing Shown to Improve Posture in People with Parkinson’s Disease
- Results from the PPMI Study on an Alpha-Synuclein Seed Amplification Assay
- Use of Continuous Circadian Intracerebroventricular Administration of Anaerobic-Dopamine Reduces Levodopa-Related Complications
- Results from a Phase III Clinical Trial for Subcutaneous Infusion of Foslevodopa/Foscarbidopa
September 14, 2021
- Reduced Quality of Life in People with Parkinson’s Disease of Minority Racial Groups
- Characteristics of Hospitalized COVID-19 Patients with Parkinson’s Disease
- Cost and Availability are Major Barriers in Genetic Testing for Parkinson’s Disease Patients
- The Promising Effects of an α-synuclein Targeted Immunotherapy in Treating Early Parkinson’s Disease
- Reduction of LRRK2 in Human Cerebrospinal Fluid with LRRK2 Small Molecule Inhibitors
- Results from Phase 2 Study of Essential Tremor Therapeutic Shows Improved Upper Limb Tremor
February 9, 2021
• The International Parkinson and Movement Disorder Society (MDS) Continues to Caution Against Unproven Cell-Based Therapies for Parkinson's Disease
September 11-15, 2020 - Virtual Congress
- Active Immunotherapeutic PD01A for Parkinson’s Disease Phase I Clinical Study
- Early Inflammation as a Potential Predictor of Severe Decline in Nigrostriatal Function
- Multicenter, Deep Brain Stimulation Study Suggests Increased Range of Effective Stimulus Amplitude Using Directional vs. Omnidirectional Leads
- The Association of Loneliness with Quality of Life and Disease Severity in Parkinson’s Disease
September 22-26, 2019 – International Congress – Nice, France
- Lower Serum Biomarkers Found in Early Untreated Parkinson’s Disease
- High Intensity Interval Training May Elevate Serum BDNF Levels in Parkinson’s Disease Patients
- Worldwide Online Survey Aims to Identify a New Comprehensive Approach to Global Collaboration for Parkinson’s Disease
- Patient’s Perception of Non-Motor and Motor Function Successfully Models Parkinson’s Disease Severity
- Safety and Biomarker Effects of Novel Therapeutic for Parkinson’s Disease with GBA Mutations
Information For Press and Media
As the largest global event dedicated to the field of Movement Disorders, the International Congress of Parkinson’s Disease and Movement Disorders ® acts as a launchpad to share hundreds of incredible scientific advancements each year. Researchers, clinicians and leaders converge to collaborate, elevate the latest findings, and direct the global conversation across the field.
For press inquiries:
Shea Higgins,
MDS Assistant Director of Communications
shiggins@movementdisorders.org
We invite members of the media to join us in sharing the emerging news as this pivotal event unfolds.
Registration
Members of the working media may receive waived registration fees for the International Congress in person, with valid credentials.
Credentials
Only representatives of the following media will be registered. You will need to provide your credentials in order to receive a press registration:
- General circulation newspapers, magazines or wire services
- Medical or health care publications
- Broadcast media
- Website writers
Advertising or marketing representatives will not be registered as press. Educational groups and nonprofits are also ineligible for press registration.
MDS considers the following to be official credentials for media:
- A recognized press card
- Business card or official contributor profile clearly showing media affiliation (a print, online or broadcast news organization) and position (editor, writer, producer, reporter, etc.)
- A letter on official letterhead from an editor of a recognized publication or a producer of a broadcast program certifying that the individual is covering the conference for the respective organization
MDS considers the following to be official credentials for freelancers:
- A letter of assignment from a medium such as those listed above.
- If you wish to attend the meeting without a specific editorial assignment, you must present credentials indicating membership in a recognized professional communications association, or submit published samples of your work along with appropriate identification.
Embargoes
In an effort to assist members of the press with planning coverage, MDS issues press releases in advance of the International Congress. However, all releases pertaining to abstracts and other research presented at the MDS International Congress are embargoed until the beginning of the event.
For 2024, all abstract embargoes will lift October 5, 2025, 08:00 HST (local Honolulu, Hawaii, USA time).
General Conditions
Onsite, no video or audio recording is allowed inside meeting rooms, sessions or the exhibition hall. On the Virtual Platform, no screen capturing or recording of on-demand sessions is permitted.
However, press will be permitted to record audio for personal note-taking purposes. Press representatives may cover all opening symposia, plenary and parallel sessions, Meet the Expert and video sessions, skills workshops and exhibits of the International Congress of Parkinson's Disease and Movement Disorders with the exception of sessions and meetings that are designated as restricted, closed or by invitation only in the Final Program.
Press Policies
*No exceptions will be made to the following:
-
Representatives of public relations/communication and pharmaceutical organizations do not have access to press conferences or other press related materials. Any individual with a press badge who sells, markets or represents a company for the purpose of obtaining advertising or subscriptions from any registrant or exhibitor will immediately forfeit press credentials for this and subsequent meetings.
- News releases regarding scientific presentations made at the MDS International Congress must be reviewed in advance by the MDS Communications staff and must be embargoed for release until October 5, 2025, 08:00 HST. All materials must be submitted to the MDS Communications staff for review by September 30, 2025.
- Materials may not indicate MDS endorsement or use the MDS logo.
- Non-MDS news briefings or other media events are prohibited in meeting areas, including hotels, during the MDS International Congress.
- Under no conditions will lists of past or current registered press be made available.
Individuals, companies, organizations or institutions found in violation of these policies will have MDS International Congress access revoked. Additional sanctions may apply.
If you have questions, please contact Shea Higgins, MDS Assistant Director of Communications, at shiggins@movementdisorders.org.